Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Inclusion Criteria

• •Histologically or cytologically confirmed recurrent or refractory non-Hodgkin's lymphoma (NHL) of any histologic subtype
• •* Indolent
• •* Follicular small cleaved cell
• •* Follicular mixed cell
• •* Small lymphocytic
• •* Mucosa-associated lymphoid tissue (MALT)
• •* Monocytoid B-cell
• •* Waldenstrom's macroglobulinemia
• •* Aggressive
• •* Follicular large cell
• •* Diffuse large cell
• •* Immunoblastic
• •* Mantle cell
• •* Ki-1+ NHL
• •* Peripheral T-cell
• •* Angiocentric and angioimmunoblastic
• •* Transformed lymphoma
• •Bidimensionally measurable disease
• •No more than 3 prior treatment regimens as follows:
• •* Primary radiotherapy is 1 regimen
• •* Combined therapy with radiotherapy and chemotherapy is 1 regimen
• •* Alternating therapy is 1 regimen
• •No known brain metastases
• •Performance status - ECOG 0-2
• •Performance status - Karnofsky 50-100%
• •WBC count at least 3,000/mm\^3
• •Absolute neutrophil count at least 1,500/mm\^3
• •Platelet count at least 100,000/mm\^3
• •Bilirubin normal
• •SGOT/SGPT no greater than 2.5 times upper limit of normal
• •Creatinine normal
• •Creatinine clearance at least 60 mL/min
• •No symptomatic congestive heart failure
• •No unstable angina pectoris
• •No cardiac arrhythmia
• •No neuropathy greater than grade 1
• •No history of allergy to platinum compounds or antiemetics
• •No uncontrolled illness
• •No active infection
• •Not pregnant or nursing
• •Fertile patients must use effective contraception
• •No concurrent colony-stimulating factors during first course of therapy
• •At least 4 weeks since prior chemotherapy
• •At least 4 weeks since prior radiotherapy
• •No other concurrent investigational drugs
• •No concurrent antiretroviral therapy for HIV-positive patients